摘要
目的探讨厄贝沙坦氢氯噻嗪联合螺内酯治疗舒张性心力衰竭(DHF)的效果及安全性。方法 120例DHF患者随机分为常规组与治疗组,常规组给予常规治疗,治疗组在常规基础上加用厄贝沙坦氢氯噻嗪联合螺内酯治疗。通过6 min步行试验和超声心动图指标舒张早期最大血流峰值速度(E峰)、舒张末期最大血流峰值速度(A峰)、E/A比值变化,监测血浆脑钠肽(BNP),比较2组临床疗效。结果 2组治疗前后比较左室舒张功能指标E峰、A峰、E/A比值、6 min步行试验、BNP改变均优于治疗前(P<0.01),并且治疗后对比治疗组优于常规组(P<0.01)。结论厄贝沙坦氢氯噻嗪联合螺内酯治疗DHF疗效显著,安全性好,值得临床推广。
Objective To explone the therapeutic effect and safety of combination of Irbesartan and Hydrochlorothiazide and sprionolactone on diastolic heart failure（DHF）.Methods 120 patients with DHF were randomly divided into two groups routine treatment group（control group） and valsartan group（experimental group） which receive treatment of Irbesartan combination Spironolactone on the basis of routin treatment.The changing of the levels of plasma brain natriuretic peptide（BNP）and the indexes of echocardiogram and 6 minute walk test（6-MWT） were observed after six months treatment and made comparison.Results The levels of BNP of both groups decreased obviously（P0.05）,the ratio of left ventricular diastolic function A peak,E peak,E/A raised singnificantly（P0.05）,the 6-MWT also have significant increased in two groups（P0.05）,the results of the experimental group improved significantly（P0.05）,and there were statistic differences in comparison with those of the control group.Conclusion Irbesartan and Spironolactone in the treatment of left ventricular diastolic heart failure（DHF） are effective and safety,which deserve clinical promotion.
出处
《基层医学论坛》
2013年第16期2047-2049,共3页
The Medical Forum
关键词
舒张性心力衰竭
厄贝沙坦氢氯噻嗪
螺内酯
BNP
Diastolic heart failure Irbesartan and Hydrochlorothiazide Spironolactone BNP
